A citation-based method for searching scientific literature

Muhannad Alqudsi, Juan Carlos Q Velez, Jose Navarrete. Curr Opin Cardiol 2021
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
100

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
370
100

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
100

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Christopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, James Mancuso, Susan Huyck, Urszula Masiukiewicz, Bernard Charbonnel, Robert Frederich, Silvina Gallo, Francesco Cosentino,[...]. N Engl J Med 2020
189
100


Bias in meta-analysis detected by a simple, graphical test.
M Egger, G Davey Smith, M Schneider, C Minder. BMJ 1997
100

Empagliflozin and Dulaglutide are Effective against Obesity-induced Airway Hyperresponsiveness and Fibrosis in A Murine Model.
Hye Jung Park, Heejae Han, Eun-Yi Oh, Sung Ryeol Kim, Kyung Hee Park, Jae-Hyun Lee, Jung-Won Park. Sci Rep 2019
8
100

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
100

Hypertension: Current trends and future perspectives.
Paul G Hunter, Fiona A Chapman, Neeraj Dhaun. Br J Clin Pharmacol 2021
1
100

Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials.
Daobo Li, Yingying Liu, Tesfaldet Habtemariam Hidru, Xiaolei Yang, Yunsong Wang, Cheng Chen, Ka Hou Christien Li, Yuqi Tang, Yushan Wei, Gary Tse,[...]. Front Endocrinol (Lausanne) 2021
1
100

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
David Moher, Alessandro Liberati, Jennifer Tetzlaff, Douglas G Altman. PLoS Med 2009
100

Random-effects model for meta-analysis of clinical trials: an update.
Rebecca DerSimonian, Raghu Kacker. Contemp Clin Trials 2007
100

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
492
100

Canagliflozin alleviates LPS-induced acute lung injury by modulating alveolar macrophage polarization.
Fengyu Lin, Chao Song, Yanjun Zeng, Yi Li, Haitao Li, Ben Liu, Minhui Dai, Pinhua Pan. Int Immunopharmacol 2020
3
100

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
100

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
100

Are SGLT2 Inhibitors New Hypertension Drugs?
Kazuomi Kario, Keith C Ferdinand, Wanpen Vongpatanasin. Circulation 2021
3
100

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.
Julian P T Higgins, Douglas G Altman, Peter C Gøtzsche, Peter Jüni, David Moher, Andrew D Oxman, Jelena Savovic, Kenneth F Schulz, Laura Weeks, Jonathan A C Sterne. BMJ 2011
100

Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.
Zien Zhou, Meg J Jardine, Qiang Li, Brendon L Neuen, Christopher P Cannon, Dick de Zeeuw, Robert Edwards, Adeera Levin, Kenneth W Mahaffey, Vlado Perkovic,[...]. Stroke 2021
4
100

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
Hang-Long Li, Gregory Y H Lip, Qi Feng, Yue Fei, Yi-Kei Tse, Mei-Zhen Wu, Qing-Wen Ren, Hung-Fat Tse, Bernard-M Y Cheung, Kai-Hang Yiu. Cardiovasc Diabetol 2021
5
100


The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension.
Biswajit Chowdhury, Albert Z Luu, Vincent Z Luu, M Golam Kabir, Yi Pan, Hwee Teoh, Adrian Quan, Sandra Sabongui, Mohammed Al-Omran, Deepak L Bhatt,[...]. Biochem Biophys Res Commun 2020
15
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.